A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

Citigroup has promoted three senior healthcare investment bankers - Sumit Khedekar, Nishant Jadav and Michael Guarino - in ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...

In its quest to stay at the top of the obesity drug market, Eli Lilly is following in Novo Nordisk's footsteps by pursuing a ...

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing more benefits of these powerful medicines, it’s no wonder appetite ...

The conditions under which GenAI will be developed in Denmark were outlined in the government’s revised National Strategy for Digitalisation (NSD), published in February 2024. The NSD was backed by a ...

The American Heart Association and the American Stroke Association issued guidelines Monday that also look at the effects of testosterone and estrogen on the body. Meanwhile, Eli Lilly sues three ...

Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

Whittier Trust Co. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities and ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...